Impact of the COVID-19 Pandemic on a Program to Screen for Subclinical Familial Pulmonary Fibrosis

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2024 May 19

PMID 38762792

Authors

Margaret L Salisbury

Cheryl R Markin

Tisra H Fadely

Adam R Guttentag

Jonathan A Kropski

Timothy S Blackwell

Affiliations

Soon will be listed here.

Citing Articles

Impact of the COVID-19 Pandemic on a Program to Screen for Subclinical Familial Pulmonary Fibrosis.

Salisbury M, Markin C, Fadely T, Guttentag A, Kropski J, Blackwell T Am J Respir Crit Care Med. 2024; 210(5):669-672.

PMID: 38762792 PMC: 11389563. DOI: 10.1164/rccm.202401-0034LE.

References

Hatabu H, Hunninghake G, Richeldi L, Brown K, Wells A, Remy-Jardin M . Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020; 8(7):726-737. PMC: 7970441. DOI: 10.1016/S2213-2600(20)30168-5. View

Myall K, Mukherjee B, Castanheira A, Lam J, Benedetti G, Mak S . Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc. 2021; 18(5):799-806. PMC: 8086530. DOI: 10.1513/AnnalsATS.202008-1002OC. View

Salisbury M, Markin C, Fadely T, Guttentag A, Kropski J, Blackwell T . Impact of the COVID-19 Pandemic on a Program to Screen for Subclinical Familial Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024; 210(5):669-672. PMC: 11389563. DOI: 10.1164/rccm.202401-0034LE. View

Morin L, Savale L, Pham T, Colle R, Figueiredo S, Harrois A . Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021; 325(15):1525-1534. PMC: 7970386. DOI: 10.1001/jama.2021.3331. View

Lerum T, Aalokken T, Bronstad E, Aarli B, Ikdahl E, Lund K . Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2020; 57(4). PMC: 7736755. DOI: 10.1183/13993003.03448-2020. View

Salisbury M, Hewlett J, Ding G, Markin C, Douglas K, Mason W . Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial Interstitial Lung Disease. Am J Respir Crit Care Med. 2020; 201(10):1230-1239. PMC: 7233345. DOI: 10.1164/rccm.201909-1834OC. View

Zhang H, Huang C, Gu X, Wang Y, Li X, Liu M . 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study. Lancet Respir Med. 2023; 12(1):55-66. DOI: 10.1016/S2213-2600(23)00387-9. View

Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata M, Navarro C, Perez-Padilla R, Vargas M . Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011; 105(12):1902-7. DOI: 10.1016/j.rmed.2011.08.022. View

Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M . Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021; 299(1):E177-E186. PMC: 7841877. DOI: 10.1148/radiol.2021203153. View

10.

Han X, Fan Y, Alwalid O, Zhang X, Jia X, Zheng Y . Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19. Radiology. 2021; 301(3):E438-E440. PMC: 8335811. DOI: 10.1148/radiol.2021210972. View

11.

Steele M, Peljto A, Mathai S, Humphries S, Bang T, Oh A . Incidence and Progression of Fibrotic Lung Disease in an At-Risk Cohort. Am J Respir Crit Care Med. 2022; 207(5):587-593. PMC: 10870916. DOI: 10.1164/rccm.202206-1075OC. View